Teva Pharmaceutical Industries Limited (TEVA) Financial Statements

Executive TeamFinancials
SegmentsShareholders

Teva Pharmaceutical Industries financial statements at a glance

Teva Pharmaceutical Industries reported revenue of $17.26 billion for fiscal year 2025 (ended December 31, 2025), up 4.3% from fiscal year 2024. Net income was $1.41 billion, a net margin of 8.2%, and diluted earnings per share were $1.21.

At the end of fiscal year 2025 it had total assets of $40.75 billion, total liabilities of $32.83 billion and shareholders' equity of $7.91 billion, with cash and short-term investments of $3.56 billion and total debt of $17.09 billion.

Its operations brought in $1.65 billion of cash; capital spending was $501.00 million, leaving free cash flow of $1.15 billion.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

TEVA logo

Teva Pharmaceutical Industries Limited

TEVAIsrael
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
17.26B
Prev Year: 16.54B
YoY: +4.3%
Operating Revenue
16.83B
Prev Year: 16.18B
YoY: +4.0%
Normalized EBITDA
4.88B
Prev Year: 4.38B
YoY: +11.4%
Tax Rate for Calcs
0.23
Prev Year: 0
Tax Effect of Unusual Items
-400.89M
Prev Year: -829.38M
YoY: +51.7%
Total Operating Income as Reported
2.16B
Prev Year: -303.00M
YoY: +811.9%
Equity in Earnings of Affiliates, Net of Tax
15.00M
Prev Year: 1.00M
YoY: +1400.0%
Other Income Expense
-1.74B
Prev Year: -3.60B
YoY: +51.6%
Other Non-operating Income (expense)
1.00M
Prev Year: 9.00M
YoY: -88.9%
Special Income Charges
-1.79B
Prev Year: -3.67B
YoY: +51.2%
Gain on Sale of Property, Plant and Equipment
2.00M
Prev Year: 2.00M
YoY: 0.0%
Gain on Sale of Business
-22.00M
Prev Year: 15.00M
YoY: -246.7%
Other Special Charges
467.00M
Prev Year: 760.00M
YoY: -38.6%
Impairment of Capital Assets
1.03B
Prev Year: 2.56B
YoY: -59.8%
Restructuring and Mergers Acquisition
279.00M
Prev Year: 377.00M
YoY: -26.0%
Gain on Sale of Securities
51.00M
Prev Year: 69.00M
YoY: -26.1%
Total Other Finance Cost
69.00M
Prev Year: 48.00M
YoY: +43.8%
Other General and Administrative
1.29B
Prev Year: 1.16B
YoY: +10.9%
Cost of Revenue
8.32B
Prev Year: 8.48B
YoY: -1.9%
Gross Profit
8.94B
Prev Year: 8.06B
YoY: +10.8%
Operating Expense
4.99B
Prev Year: 4.70B
YoY: +6.1%
Selling General and Administrative
3.97B
Prev Year: 3.70B
YoY: +7.3%
General and Administrative Expense
1.29B
Prev Year: 1.16B
YoY: +10.9%
Selling and Marketing Expense
2.69B
Prev Year: 2.54B
YoY: +5.7%
Research and Development
1.01B
Prev Year: 998.00M
YoY: +1.5%
Operating Income
3.95B
Prev Year: 3.36B
YoY: +17.5%
Net Non Operating Interest Income Expense
-985.00M
Prev Year: -1.05B
YoY: +6.2%
Non-operating Interest Expense
916.00M
Prev Year: 1.00B
YoY: -8.6%
Pre-tax Income
1.22B
Prev Year: -1.28B
YoY: +195.2%
Provision for Income Taxes
-180.00M
Prev Year: 676.00M
YoY: -126.6%
Net Income Common Stockholders
1.41B
Prev Year: -1.64B
YoY: +186.0%
Net Income
1.41B
Prev Year: -1.64B
YoY: +186.0%
Net Income Including Non-Controlling Interests
1.42B
Prev Year: -1.96B
YoY: +172.4%
Net Income from Continuing Operations
1.42B
Prev Year: -1.96B
YoY: +172.4%
Noncontrolling Interests
-7.00M
Prev Year: 320.00M
YoY: -102.2%
Diluted NI Available to Com Stockholders
1.41B
Prev Year: -1.64B
YoY: +186.0%
Basic EPS
1.23
Prev Year: -1.45
YoY: +184.8%
Diluted EPS
1.21
Prev Year: -1.45
YoY: +183.4%
Weighted Average Shares (basic)
1.15B
Prev Year: 1.13B
YoY: +1.2%
Weighted Average Shares (diluted)
1.16B
Prev Year: 1.13B
YoY: +2.8%
Total Expenses
13.31B
Prev Year: 13.18B
YoY: +0.9%
Net Income from Continuing and Discontinued Operation
1.41B
Prev Year: -1.64B
YoY: +186.0%
Normalized Income
2.75B
Prev Year: 1.14B
YoY: +141.9%
Interest Expense
916.00M
Prev Year: 1.00B
YoY: -8.6%
Net Interest Income
-985.00M
Prev Year: -1.05B
YoY: +6.2%
EBIT
2.14B
Prev Year: -282.00M
YoY: +858.5%
EBITDA
3.14B
Prev Year: 777.00M
YoY: +304.2%
Reconciled Cost of Revenue
8.32B
Prev Year: 8.48B
YoY: -1.9%
Reconciled Depreciation
1.00B
Prev Year: 1.06B
YoY: -5.4%
Net Income from Continuing Operation Net Minority Interest
1.41B
Prev Year: -1.64B
YoY: +186.0%
Total Unusual Items Excluding Goodwill
-1.74B
Prev Year: -3.61B
YoY: +51.7%
Total Unusual Items
-1.74B
Prev Year: -3.61B
YoY: +51.7%
Values in USD

Teva Pharmaceutical Industries key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$17.3B$16.5B$15.8B$14.9B$15.9B
Gross profit$8.9B$8.1B$7.6B$7.0B$7.6B
Operating income$4.0B$3.4B$3.2B$2.7B$3.1B
Net income$1.4B-$1.6B-$559.0M-$2.4B$417.0M
Diluted EPS$1.21-$1.45-$0.50-$2.12$0.38
Total assets$40.7B$39.3B$43.5B$44.0B$47.7B
Total liabilities$32.8B$33.6B$35.4B$35.4B$36.4B
Shareholders' equity$7.9B$5.4B$7.5B$7.8B$10.3B
Cash and short-term investments$3.6B$3.3B$3.2B$2.8B$2.2B
Total debt$17.1B$18.1B$20.2B$21.6B$23.5B
Operating cash flow$1.6B$1.2B$1.4B$1.6B$798.0M
Capital spending$501.0M$498.0M$526.0M$548.0M$562.0M
Free cash flow$1.1B$749.0M$842.0M$1.0B$236.0M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was Teva Pharmaceutical Industries's revenue in fiscal year 2025?

$17.26 billion, up 4.3% from $16.54 billion in fiscal year 2024.

How much profit does Teva Pharmaceutical Industries make?

Teva Pharmaceutical Industries reported net income of $1.41 billion for fiscal year 2025 (8.2% of revenue); operating income was $3.95 billion.

How much cash and debt does Teva Pharmaceutical Industries have?

At the end of fiscal year 2025: cash and short-term investments of $3.56 billion and total debt of $17.09 billion.

What is Teva Pharmaceutical Industries's free cash flow?

$1.15 billion in fiscal year 2025 (operating cash flow of $1.65 billion minus capital spending of $501.00 million).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube